Exabis Library
Welcome to the e-CCO Library!
P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn’s disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P325: Combination therapy with adalimumab and immunomodulators decreases incidence of intestinal resection in Crohn's disease patients previously treated with infliximab: a large, multicentre cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P325: Efficacy, safety, and long-term outcome of endoscopic dilation therapy for stricturing Crohn’s disease of the upper gastrointestinal tract: a combined analysis of 127 endoscopic balloon dilation procedures
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P325: Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P325: Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P325: Proton pump inhibitors are associated with a disabling course of Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P325: Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P325: Risk factors for lymph node involvement in patients undergoing ileal pouch-anal anastomosis for ulcerative colitis complicated by colorectal cancer in the biological years
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P326 Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P326: An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P326: Audit and review of infliximab therapeutic drug monitoring and prescribing practices in paediatric inflammatory bowel disease (IBD) patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P326: Efficacy of vedolizumab on patient-reported outcomes in ulcerative colitis patients: results from a prospective German observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P326: Physicians’ recommendations for travel in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P326: PREFAB-study: PRediction tool for Early identification of patients at risk of Crohn's disease in perianal Fistulas and ABscesses: interim analysis of a prospective pilot study at a non-academic, IBD-expert centre in the Netherlands
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P326: The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P326: Validation of CUCQ-8 Questionnaire for Quality of Life Assessment in IBD Patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P327 Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P327: Biosimilar infliximab in real-life Crohn’s disease’s anti-TNFalfa naïve patients: a comparative observational cohort study (SIMRECRO study)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P327: Characteristics of esophago-gastro-duodenal Crohn's disease in the biologic era: a nationwide study of the Young GETECCU Group
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P327: Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM